NO300845B1 - Substituerte tienyl- eller pyrrolylkarboksylsyrederivater, og medisiner som inneholder dem - Google Patents
Substituerte tienyl- eller pyrrolylkarboksylsyrederivater, og medisiner som inneholder dem Download PDFInfo
- Publication number
- NO300845B1 NO300845B1 NO933051A NO933051A NO300845B1 NO 300845 B1 NO300845 B1 NO 300845B1 NO 933051 A NO933051 A NO 933051A NO 933051 A NO933051 A NO 933051A NO 300845 B1 NO300845 B1 NO 300845B1
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- phenyl
- benzyl
- alkoxy
- formula
- Prior art date
Links
- 125000001544 thienyl group Chemical group 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title abstract description 3
- 229940079593 drug Drugs 0.000 title description 2
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical class OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 15
- -1 benzyloxy, benzyl Chemical group 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 8
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 5
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 2
- 125000004846 (C1-C4) allyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 5
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 4
- LOAUVZALPPNFOQ-UHFFFAOYSA-M quinaldate Chemical compound C1=CC=CC2=NC(C(=O)[O-])=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-M 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000006228 Dieckmann condensation reaction Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000005054 naphthyridines Chemical class 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XCFUFRWRMISKRZ-UHFFFAOYSA-N 1,5-naphthyridine-2-carboxylic acid Chemical compound N1=CC=CC2=NC(C(=O)O)=CC=C21 XCFUFRWRMISKRZ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- WWWFBYZDEPDSOR-UHFFFAOYSA-N 10-hydroxy-12-methyl-N,N-dipropyl-3-thia-7,10-diazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide Chemical compound ON1C(C(=O)N(CCC)CCC)=C(C)C2=C1C=NC1=C2SC=C1 WWWFBYZDEPDSOR-UHFFFAOYSA-N 0.000 description 1
- HUWPGKCDHNUBGH-UHFFFAOYSA-N 1h-pyrrolo[3,2-c][1,8]naphthyridine Chemical compound N1=CC=CC2=C(NC=C3)C3=CN=C21 HUWPGKCDHNUBGH-UHFFFAOYSA-N 0.000 description 1
- ANFOMGVCGLRXAC-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine-2-carboxylic acid Chemical class N1=CC=C2NC(C(=O)O)=CC2=C1 ANFOMGVCGLRXAC-UHFFFAOYSA-N 0.000 description 1
- VNDWOJHEQHSSJU-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]quinoline Chemical compound C1=CC=CC2=C(NC=C3)C3=CN=C21 VNDWOJHEQHSSJU-UHFFFAOYSA-N 0.000 description 1
- NJCFYJXPDSCLAK-UHFFFAOYSA-N 2-(methylamino)-n,n-dipropylacetamide Chemical compound CCCN(CCC)C(=O)CNC NJCFYJXPDSCLAK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VZKRMFRHRDKVQX-UHFFFAOYSA-N 2-[[3-cyano-6-(diethylamino)-2-methylquinolin-4-yl]amino]acetamide Chemical compound N1=C(C)C(C#N)=C(NCC(N)=O)C2=CC(N(CC)CC)=CC=C21 VZKRMFRHRDKVQX-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- PHJFVCMMPGGIDV-UHFFFAOYSA-N 2-anilinoprop-2-enoic acid Chemical compound OC(=O)C(=C)NC1=CC=CC=C1 PHJFVCMMPGGIDV-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- AVAQZFUVMGMHSC-UHFFFAOYSA-N 2-cyano-3-ethoxyprop-2-enoic acid Chemical compound CCOC=C(C#N)C(O)=O AVAQZFUVMGMHSC-UHFFFAOYSA-N 0.000 description 1
- MJFQLBQQPADLHK-UHFFFAOYSA-N 4-chloro-6-(diethylamino)-2-methylsulfanylquinoline-3-carbonitrile Chemical compound N1=C(SC)C(C#N)=C(Cl)C2=CC(N(CC)CC)=CC=C21 MJFQLBQQPADLHK-UHFFFAOYSA-N 0.000 description 1
- VDEFGIDDJHLHBD-UHFFFAOYSA-N 4-chloro-6-(diethylamino)-8-methylquinoline-3-carbonitrile Chemical compound N1=CC(C#N)=C(Cl)C2=CC(N(CC)CC)=CC(C)=C21 VDEFGIDDJHLHBD-UHFFFAOYSA-N 0.000 description 1
- XBTWVJKPQPQTDW-UHFFFAOYSA-N 4-n,4-n-diethyl-2-methylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C(C)=C1 XBTWVJKPQPQTDW-UHFFFAOYSA-N 0.000 description 1
- BKWJGCKJAZLCAZ-UHFFFAOYSA-N 6-(diethylamino)-2-methyl-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1=C(C)C(C#N)=C(O)C2=CC(N(CC)CC)=CC=C21 BKWJGCKJAZLCAZ-UHFFFAOYSA-N 0.000 description 1
- FFGIAUZDAKWXMU-UHFFFAOYSA-N 6-(diethylamino)-2-methylsulfanyl-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1=C(SC)C(C#N)=C(O)C2=CC(N(CC)CC)=CC=C21 FFGIAUZDAKWXMU-UHFFFAOYSA-N 0.000 description 1
- RTHKWMAFQYEAPP-UHFFFAOYSA-N 6-(diethylamino)-8-methyl-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1=CC(C#N)=C(O)C2=CC(N(CC)CC)=CC(C)=C21 RTHKWMAFQYEAPP-UHFFFAOYSA-N 0.000 description 1
- KSVBTGMNWMJRMI-UHFFFAOYSA-N 8-(diethylamino)-3-ethoxy-1-methyl-n,n-dipropylpyrrolo[3,2-c]quinoline-2-carboxamide Chemical compound C1=CC(N(CC)CC)=CC2=C(N(C(C(=O)N(CCC)CCC)=C3OCC)C)C3=CN=C21 KSVBTGMNWMJRMI-UHFFFAOYSA-N 0.000 description 1
- CFSVOBIQXQPYSL-UHFFFAOYSA-N 8-(diethylamino)-3-hydroxy-1-methyl-n,n-dipropylpyrrolo[3,2-c]quinoline-2-carboxamide Chemical compound C1=CC(N(CC)CC)=CC2=C(N(C(C(=O)N(CCC)CCC)=C3O)C)C3=CN=C21 CFSVOBIQXQPYSL-UHFFFAOYSA-N 0.000 description 1
- WCHRWTHJNWRWKZ-UHFFFAOYSA-N 8-chloro-3-hydroxy-1-methyl-n,n-dipropylpyrrolo[3,2-c]quinoline-2-carboxamide Chemical compound C1=CC(Cl)=CC2=C(N(C(C(=O)N(CCC)CCC)=C3O)C)C3=CN=C21 WCHRWTHJNWRWKZ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- RKZGGIIIMLTFDE-UHFFFAOYSA-N CCCN(CCC)C(=O)CN(C)C1=C(C(=O)OCC)C=NC2=C1SC=C2 Chemical compound CCCN(CCC)C(=O)CN(C)C1=C(C(=O)OCC)C=NC2=C1SC=C2 RKZGGIIIMLTFDE-UHFFFAOYSA-N 0.000 description 1
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DJUKGXDLJNBXJS-UHFFFAOYSA-N dithieno[2,3-a:2',3'-d]pyridine Chemical group N1=C2C=CSC2=C2SC=CC2=C1 DJUKGXDLJNBXJS-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- DBDHAAVGVBSFLG-UHFFFAOYSA-N ethyl 2-[[3-cyano-6-(diethylamino)-2-methylsulfanylquinolin-4-yl]amino]acetate Chemical compound C1=C(N(CC)CC)C=C2C(NCC(=O)OCC)=C(C#N)C(SC)=NC2=C1 DBDHAAVGVBSFLG-UHFFFAOYSA-N 0.000 description 1
- POABRARINOCORV-UHFFFAOYSA-N ethyl 2-cyano-3,3-bis(methylsulfanyl)prop-2-enoate Chemical compound CCOC(=O)C(C#N)=C(SC)SC POABRARINOCORV-UHFFFAOYSA-N 0.000 description 1
- STTYEFFPKDNAJY-UHFFFAOYSA-N ethyl 2-cyano-3-[4-(diethylamino)-2-methylanilino]prop-2-enoate Chemical compound CCOC(=O)C(C#N)=CNC1=CC=C(N(CC)CC)C=C1C STTYEFFPKDNAJY-UHFFFAOYSA-N 0.000 description 1
- KBNOHXXZCQPFOL-UHFFFAOYSA-N ethyl 2-cyano-3-[4-(diethylamino)anilino]-3-methylsulfanylprop-2-enoate Chemical compound CCOC(=O)C(C#N)=C(SC)NC1=CC=C(N(CC)CC)C=C1 KBNOHXXZCQPFOL-UHFFFAOYSA-N 0.000 description 1
- YKXFOGAYPIPTKF-UHFFFAOYSA-N ethyl 2-cyano-3-ethoxybut-2-enoate Chemical compound CCOC(C)=C(C#N)C(=O)OCC YKXFOGAYPIPTKF-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- IEMYKIJFCCTLTH-UHFFFAOYSA-N ethyl 4,6-dichloro-1,5-naphthyridine-3-carboxylate Chemical compound C1=CC(Cl)=NC2=C(Cl)C(C(=O)OCC)=CN=C21 IEMYKIJFCCTLTH-UHFFFAOYSA-N 0.000 description 1
- MEWMHDFPHVZSIX-UHFFFAOYSA-N ethyl 4-chloro-6-(diethylamino)quinoline-3-carboxylate Chemical compound C1=CC(N(CC)CC)=CC2=C(Cl)C(C(=O)OCC)=CN=C21 MEWMHDFPHVZSIX-UHFFFAOYSA-N 0.000 description 1
- JRIBGWJATSMEGD-UHFFFAOYSA-N ethyl 6-(diethylamino)-4-[[2-(dipropylamino)-2-oxoethyl]-methylamino]quinoline-3-carboxylate Chemical compound C1=C(N(CC)CC)C=C2C(N(C)CC(=O)N(CCC)CCC)=C(C(=O)OCC)C=NC2=C1 JRIBGWJATSMEGD-UHFFFAOYSA-N 0.000 description 1
- XKLRNNBZGUFWCE-UHFFFAOYSA-N ethyl 6-chloro-4-[[2-(dipropylamino)-2-oxoethyl]-methylamino]quinoline-3-carboxylate Chemical compound C1=C(Cl)C=C2C(N(C)CC(=O)N(CCC)CCC)=C(C(=O)OCC)C=NC2=C1 XKLRNNBZGUFWCE-UHFFFAOYSA-N 0.000 description 1
- BMGRDHCUAJOXDZ-UHFFFAOYSA-N ethyl 7-chlorothieno[3,2-b]pyridine-6-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CSC2=C1Cl BMGRDHCUAJOXDZ-UHFFFAOYSA-N 0.000 description 1
- WVXUVVDDUHEOBM-UHFFFAOYSA-N ethyl 7-oxo-4h-thieno[3,2-b]pyridine-6-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CSC2=C1O WVXUVVDDUHEOBM-UHFFFAOYSA-N 0.000 description 1
- XXJXMMJCUWOYPL-UHFFFAOYSA-N ethyl 8-(diethylamino)-3-hydroxythieno[3,2-c]quinoline-2-carboxylate Chemical compound C1=C(N(CC)CC)C=C2C(SC(=C3O)C(=O)OCC)=C3C=NC2=C1 XXJXMMJCUWOYPL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003511 tertiary amides Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- IEWVLMJXSSWNQY-UHFFFAOYSA-N thieno[2,3-h]quinoline Chemical compound C1=CN=C2C(C=CS3)=C3C=CC2=C1 IEWVLMJXSSWNQY-UHFFFAOYSA-N 0.000 description 1
- PLYHRKDXZVDSMP-UHFFFAOYSA-N thieno[3,2-c][1,8]naphthyridine Chemical compound N1=CC=CC2=C(SC=C3)C3=CN=C21 PLYHRKDXZVDSMP-UHFFFAOYSA-N 0.000 description 1
- CQMCNAJHSNWQMJ-UHFFFAOYSA-N thieno[3,2-c]quinoline Chemical compound C1=CC=CC2=C(SC=C3)C3=CN=C21 CQMCNAJHSNWQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002175 thienopyridine Chemical class 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Toys (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9210329A FR2695126B1 (fr) | 1992-08-27 | 1992-08-27 | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933051D0 NO933051D0 (no) | 1993-08-26 |
| NO933051L NO933051L (no) | 1994-02-28 |
| NO300845B1 true NO300845B1 (no) | 1997-08-04 |
Family
ID=9433050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO933051A NO300845B1 (no) | 1992-08-27 | 1993-08-26 | Substituerte tienyl- eller pyrrolylkarboksylsyrederivater, og medisiner som inneholder dem |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5360799A (de) |
| EP (1) | EP0587473B1 (de) |
| JP (1) | JPH06184145A (de) |
| KR (1) | KR100267802B1 (de) |
| AT (1) | ATE173258T1 (de) |
| AU (1) | AU659027B2 (de) |
| CA (1) | CA2104883A1 (de) |
| DE (1) | DE69322033T2 (de) |
| DK (1) | DK0587473T3 (de) |
| ES (1) | ES2125315T3 (de) |
| FI (1) | FI103889B (de) |
| FR (1) | FR2695126B1 (de) |
| GR (1) | GR3029283T3 (de) |
| HU (1) | HU217623B (de) |
| MX (1) | MX9305181A (de) |
| NO (1) | NO300845B1 (de) |
| NZ (1) | NZ248498A (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003256650A1 (en) * | 2002-07-19 | 2004-02-09 | Pharmacia Corporation | Substituted thiophene carboxamide compounds for the treatment of inflammation |
| GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
| CN103214483B (zh) | 2005-12-13 | 2014-12-17 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶 |
| CN101679357A (zh) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
| WO2008154447A1 (en) * | 2007-06-08 | 2008-12-18 | Helicon Therapeutics, Inc. | Therapeutic pyrazolonaphthyridine derivatives |
| WO2009027393A2 (en) | 2007-08-27 | 2009-03-05 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| JP4719317B2 (ja) * | 2008-02-26 | 2011-07-06 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| AU2009295936B2 (en) | 2008-09-24 | 2014-07-17 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
| DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
| EP2451804B1 (de) | 2009-07-06 | 2014-04-30 | Basf Se | Pyridazinverbindungen zur bekämpfung von wirbellosen schädlingen |
| WO2011009804A2 (en) | 2009-07-24 | 2011-01-27 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 |
| AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| EP3030227B1 (de) | 2013-08-07 | 2020-04-08 | Incyte Corporation | Dosierungsformen mit anhaltender freisetzung für einen jak1-inhibitor |
| CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| JP2018537450A (ja) | 2015-11-16 | 2018-12-20 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | Ｄｎａメチルトランスフェラーゼ阻害剤としての新規化合物 |
| JP2021519775A (ja) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| US11897883B1 (en) | 2023-09-01 | 2024-02-13 | King Faisal University | Pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| US11891377B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| US11866437B1 (en) | 2023-09-15 | 2024-01-09 | King Faisal University | 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors |
| US11952378B1 (en) | 2023-12-14 | 2024-04-09 | King Faisal University | Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887570A (en) * | 1973-09-28 | 1975-06-03 | Squibb & Sons Inc | Derivatives of pyrazolo(3,4-b)thieno(2,3-d)pyridine-2-carboxylic acids |
-
1992
- 1992-08-27 FR FR9210329A patent/FR2695126B1/fr not_active Expired - Fee Related
-
1993
- 1993-08-19 US US08/109,073 patent/US5360799A/en not_active Expired - Fee Related
- 1993-08-20 AU AU44747/93A patent/AU659027B2/en not_active Ceased
- 1993-08-25 DE DE69322033T patent/DE69322033T2/de not_active Expired - Fee Related
- 1993-08-25 DK DK93402095T patent/DK0587473T3/da active
- 1993-08-25 NZ NZ248498A patent/NZ248498A/en unknown
- 1993-08-25 ES ES93402095T patent/ES2125315T3/es not_active Expired - Lifetime
- 1993-08-25 EP EP93402095A patent/EP0587473B1/de not_active Expired - Lifetime
- 1993-08-25 AT AT93402095T patent/ATE173258T1/de not_active IP Right Cessation
- 1993-08-26 NO NO933051A patent/NO300845B1/no not_active IP Right Cessation
- 1993-08-26 JP JP5211451A patent/JPH06184145A/ja active Pending
- 1993-08-26 FI FI933756A patent/FI103889B/fi active
- 1993-08-26 CA CA002104883A patent/CA2104883A1/fr not_active Abandoned
- 1993-08-26 HU HU9302425A patent/HU217623B/hu not_active IP Right Cessation
- 1993-08-26 MX MX9305181A patent/MX9305181A/es not_active IP Right Cessation
- 1993-08-27 KR KR1019930017022A patent/KR100267802B1/ko not_active IP Right Cessation
-
1994
- 1994-07-12 US US08/273,943 patent/US5468750A/en not_active Expired - Fee Related
-
1999
- 1999-02-03 GR GR990400363T patent/GR3029283T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO933051L (no) | 1994-02-28 |
| JPH06184145A (ja) | 1994-07-05 |
| US5360799A (en) | 1994-11-01 |
| GR3029283T3 (en) | 1999-05-28 |
| FR2695126A1 (fr) | 1994-03-04 |
| DE69322033D1 (de) | 1998-12-17 |
| NO933051D0 (no) | 1993-08-26 |
| KR100267802B1 (ko) | 2000-11-01 |
| CA2104883A1 (fr) | 1994-02-28 |
| KR940003958A (ko) | 1994-03-14 |
| FR2695126B1 (fr) | 1994-11-10 |
| HUT64957A (en) | 1994-03-28 |
| FI933756A0 (fi) | 1993-08-26 |
| US5468750A (en) | 1995-11-21 |
| EP0587473B1 (de) | 1998-11-11 |
| HU9302425D0 (en) | 1993-11-29 |
| FI933756A (fi) | 1994-02-28 |
| NZ248498A (en) | 1994-09-27 |
| AU659027B2 (en) | 1995-05-04 |
| AU4474793A (en) | 1994-03-03 |
| DE69322033T2 (de) | 1999-06-17 |
| MX9305181A (es) | 1994-06-30 |
| FI103889B1 (fi) | 1999-10-15 |
| FI103889B (fi) | 1999-10-15 |
| EP0587473A1 (de) | 1994-03-16 |
| DK0587473T3 (da) | 1999-07-26 |
| ATE173258T1 (de) | 1998-11-15 |
| HU217623B (hu) | 2000-03-28 |
| ES2125315T3 (es) | 1999-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300845B1 (no) | Substituerte tienyl- eller pyrrolylkarboksylsyrederivater, og medisiner som inneholder dem | |
| AU678295B2 (en) | Heterocyclic carboxamides as tachykinin receptor antagonists | |
| AU763463B2 (en) | Tetrahydropyridoethers | |
| US5026711A (en) | 4-amino quinolines and naphthyridines and their use as medicines | |
| ZA200601715B (en) | Pyrimidothiophene compounds | |
| NZ227125A (en) | Quinazoline derivatives and pharmaceutical compositions | |
| SK280822B6 (sk) | Imidazopyridíny, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie | |
| PL147392B1 (en) | Method of obtaining novel derivatives of 1,4-dihydronaphtidrine and their salts | |
| CN110066281B (zh) | 多靶点抗肿瘤活性的吴茱萸碱衍生物及其制备方法与应用 | |
| FI89489C (fi) | Foerfarande foer framstaellning av heteroaryl-3-oxo-propanamidderivat | |
| KR910002645B1 (ko) | 6,7-이치환 1-시클로프로필-1,4-디히드로-4-옥소-1,8-나프티리딘-3-카르복실산의 제조방법 | |
| CZ105596A3 (en) | ALKOXYALKYL CARBAMATES OF IMIDAZO(1,2-a)PYRIDINES | |
| JPH08337583A (ja) | 複素環化合物およびその製造法 | |
| JPH0311067A (ja) | 興奮性アミノ酸拮抗剤 | |
| CN1326852C (zh) | 苯并呋喃衍生物 | |
| FI91405C (fi) | Menetelmä biologisesti aktiivisten kinnoliini-karboksamidien valmistamiseksi | |
| US4996213A (en) | Derivatives of 4-amino 3-carboxy naphthyridines and their pharmaceutical compositions | |
| CA2209422C (en) | 4-amino-3-acylnaphthyridine derivatives | |
| EP0126970A2 (de) | Anxiolytische und anti-depressante Thienopyridinderivate | |
| KR970005298B1 (ko) | 퀴놀린계 유도체와 그의 제조방법 | |
| EP1776369A1 (de) | Thienopyridoncarbonsäureamide und deren medizinische verwendung | |
| SU1456015A3 (ru) | Способ получени производных 1,8-нафтиридина или их кислотно-аддитивных солей (его варианты) | |
| CN113185505A (zh) | 一种喹诺酮基噁唑烷酮类化合物及其制备方法和用途 | |
| Kökösi et al. | Nitrogen bridgehead compounds. Part 19. Synthesis of polymethylenepyrimidin‐4‐ones | |
| EP0486586B1 (de) | Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN FEBRUARY 2002 |